{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:05:15Z","timestamp":1793261115431,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vhri.2024.100991","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T10:58:31Z","timestamp":1715165911000},"page":"100991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-2446","authenticated-orcid":false,"given":"Gaurav","family":"Jyani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-2631","authenticated-orcid":false,"given":"Nidhi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vhri.2024.100991_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.vhri.2024.100991_bib2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/GO.20.00032","article-title":"Chronic lymphocytic leukemia: real-world data from India","volume":"6","author":"Tejaswi","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"11","key":"10.1016\/j.vhri.2024.100991_bib3","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00277-023-05342-y","article-title":"Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia","volume":"102","author":"Hegde","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.vhri.2024.100991_bib4","article-title":"Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India","volume":"13","author":"Nehra","year":"2023","journal-title":"Lancet Reg Health Southeast East Asia"},{"key":"10.1016\/j.vhri.2024.100991_bib5","article-title":"Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment","volume":"16","author":"Sharma","year":"2023","journal-title":"Lancet Reg Health Southeast East Asia"},{"issue":"2","key":"10.1016\/j.vhri.2024.100991_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065591","article-title":"Protocol for estimating the willingness-to-pay-based value for a quality-adjusted life year to aid health technology assessment in India: a cross-sectional study","volume":"13","author":"Chugh","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vhri.2024.100991_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0272989X20973201","article-title":"Extrapolating parametric survival models in health technology assessment: a simulation study","volume":"41","author":"Gallacher","year":"2021","journal-title":"Med Decis Mak"},{"issue":"4","key":"10.1016\/j.vhri.2024.100991_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4103\/ijc.IJC_22_21","article-title":"What is the best method for long-term survival analysis?","volume":"59","author":"Bekiroglu","year":"2022","journal-title":"Indian J Cancer"},{"issue":"7","key":"10.1016\/j.vhri.2024.100991_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","article-title":"Development of an EQ-5D value set for India using an extended design (DEVINE) study: the Indian 5-Level version EQ-5D Value Set","volume":"25","author":"Jyani","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vhri.2024.100991_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/0272989X231180134","article-title":"Evaluation of EuroQol valuation technology (EQ-VT) designs to generate national value sets: learnings from the development of an EQ-5D value Set for India using an extended design (DEVINE) study","volume":"43","author":"Jyani","year":"2023","journal-title":"Med Decis Mak"},{"issue":"6","key":"10.1016\/j.vhri.2024.100991_bib11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40258-021-00668-y","article-title":"National methodological guidelines to conduct budget impact analysis for health technology assessment in India","volume":"19","author":"Prinja","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"10.1016\/j.vhri.2024.100991_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737167.2021.1921575","article-title":"Adapting health technology assessment for drugs, medical devices, and health programs: methodological considerations from the Indian experience","volume":"21","author":"Prinja","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:01:16Z","timestamp":1751371276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":12,"alternative-id":["S2212109924000244"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.100991","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.100991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100991"}}